AVIGI Therapeutics is pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements.
Their approach centers around biomimicy selectively targeting central cascades that drive disease. Their lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.